bingoskillz|美股异动丨诺和诺德跌超2%，安进减肥新药中期试验获积极数据

Novo Nordisk (LLYbingoskillz.US) fell more than 2% to $121.29. In the news, Amgen's mid-term trial of a new weight-loss drug has received positive data. If the drug is approved, it will cooperate with Novo Nordisk.bingoskillzWegovy and Lilly's Zepbound compete.

Earlier, some media said that Amgen is trying a new weight-loss drug, whose mechanism of action is different from Novo Nordisk and Lilly products, which can prevent patients from gaining weight even if they stop taking the drug.